Doctor and patient

Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.



Pursue multiple programmes
  • Increase potential success rate
  • Mitigate development risk
Seek collaboration partners
  • Spread financial cost and risk
  • Introduce specialist research expertise

Develop programmes to pre-clinical/
early clinical development

  • Minimise ongoing development risk
  • Move up value chain
  • Potential for higher deal values
  • @Sareumplc Latest tweet

    $SAR.L Sareum Holdings raises over a £1mln to advance preclinical work on its TYK2/JAK1 drugs… via @Sareumplc
    View more